CN111035609A - Micromolecular polypeptide eye essence and preparation method thereof - Google Patents
Micromolecular polypeptide eye essence and preparation method thereof Download PDFInfo
- Publication number
- CN111035609A CN111035609A CN202010027824.3A CN202010027824A CN111035609A CN 111035609 A CN111035609 A CN 111035609A CN 202010027824 A CN202010027824 A CN 202010027824A CN 111035609 A CN111035609 A CN 111035609A
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- eye essence
- mixed solution
- small
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 50
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title description 8
- 210000000130 stem cell Anatomy 0.000 claims abstract description 23
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 239000011259 mixed solution Substances 0.000 claims abstract description 19
- 150000003384 small molecules Chemical class 0.000 claims abstract description 19
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 6
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 6
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 6
- 229910052802 copper Inorganic materials 0.000 claims abstract description 6
- 239000010949 copper Substances 0.000 claims abstract description 6
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims abstract description 5
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 5
- 108010087806 Carnosine Proteins 0.000 claims abstract description 5
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims abstract description 5
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims abstract description 5
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 5
- 229940044199 carnosine Drugs 0.000 claims abstract description 5
- BSXFOBDOGHFWOC-KRCBVYEFSA-N (2S)-1-[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@H](NC(=O)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 BSXFOBDOGHFWOC-KRCBVYEFSA-N 0.000 claims abstract description 4
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims abstract description 4
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 4
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 claims abstract description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims abstract description 3
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims abstract description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 15
- 239000003906 humectant Substances 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- -1 PH regulators Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 8
- 239000000043 antiallergic agent Substances 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 210000003954 umbilical cord Anatomy 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical group [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 2
- 229940043234 carbomer-940 Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- 230000003169 placental effect Effects 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 18
- 230000037303 wrinkles Effects 0.000 abstract description 11
- 230000037394 skin elasticity Effects 0.000 abstract description 10
- 238000013329 compounding Methods 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 33
- 238000012360 testing method Methods 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000002673 Dioscorea communis Nutrition 0.000 description 2
- 241000544230 Dioscorea communis Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 208000035753 Periorbital contusion Diseases 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QGGBBQJHVCVVKM-XOBYPWAZSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amin Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(N)=O QGGBBQJHVCVVKM-XOBYPWAZSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 241000471262 Ardisia japonica Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- YDSVPIYLRFZLAT-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N Chemical compound C(C)(=O)O.C(C)(=O)O.NC(CCC(=O)NCC1=CC=CC=C1)N YDSVPIYLRFZLAT-UHFFFAOYSA-N 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 206010052139 Eye oedema Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 206010050637 Skin tightness Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 229940078033 acetyl octapeptide-3 Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940047169 astragalus root extract Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a small-molecule polypeptide eye essence which comprises the following components: oligopeptide mixed solution, micromolecular polypeptide mixed solution, stem cell mixed solution, deep-sea collagen powder and auxiliary agent; the oligopeptide mixed solution consists of oligopeptide-1, oligopeptide-3, oligopeptide-4 and oligopeptide-5; the mixed solution of the small molecular polypeptide consists of tripeptide-1 copper, palmitoyl pentapeptide-4, acetyl tetrapeptide-15, dipeptide-2, acetyl hexapeptide-8, tripeptide-1, nonapeptide-1, palmitoyl tetrapeptide-7 and carnosine. The eye essence is prepared by carefully compounding a plurality of micromolecular polypeptides and stem cell mixed liquid, has an obvious effect of improving melanin inhibition of eye skin, and has the effects of improving skin elasticity, resisting wrinkles and tightening skin.
Description
Technical Field
The invention relates to the technical field of cosmetics, and particularly relates to small-molecule polypeptide eye essence and a preparation method thereof.
Background
The eye essence is a gel essence, has fresh texture and easy absorption, can be supplemented at any time according to personal needs and skin conditions, and can improve dark eye circles, looseness and edema, promote blood circulation, tighten skin around eyes and the like due to relatively high-concentration essence components of the eye essence. Conventional eye essence generally includes main components: water, humectant, thickener, antiseptic, and plant extract.
Chinese patent CN106491460A discloses an eye essence comprising a humectant; a thickener; a skin conditioning agent; a preservative; water, the skin conditioning agent comprising: ginseng extract, rehmannia root extract, astragalus root extract, rhodiola root extract and motherwort extract. The eye essence disclosed by the invention is prepared by compounding the humectant with the traditional Chinese medicine extract, can improve dark circles, fade fine lines, remove pouches, resist wrinkles and aging, has a lasting moisturizing effect, and can mildly, finely and moisturize sensitive eye skin.
Chinese patent CN106333885A discloses a plant extract and eye essence, wherein the plant extract comprises elderberry extract, ardisia japonica extract, olive leaf extract and jujube extract. The eye essence consists of the following components: 2 to 11 percent of plant extract, 5 to 10 percent of humectant, 0.5 to 1 percent of natural preservative, 0.1 to 0.3 percent of thickening agent, 0.1 to 0.3 percent of pH regulator and the balance of water. The eye essence contains various natural plant extracts, has effects of resisting radiation, improving resistance and immunity of eye cells, regenerating and strengthening retina, optic nerve and optic blood vessel, accelerating eye blood microcirculation, and improving vision; meanwhile, the skin cell aging is delayed, the skin hydration degree and roughness are improved, the skin renewal speed is accelerated, the generation of wrinkles is improved and prevented, and the skin tightness is promoted.
The small molecular polypeptide is a biochemical substance between amino acid and protein, has a molecular weight smaller than that of protein and larger than that of amino acid, and is a fragment of protein. Two or more amino acids are linked by peptide bonds, and the resulting amino acid chain is called a peptide. Peptides consisting of 2 to 15 amino acids are called small peptides or small peptides. Among them, peptides consisting of 2 to 9 amino acids are called oligopeptides, and peptides consisting of 10 to 15 amino acids or more are called polypeptides.
Chinese patent CN110115699A discloses an eye essence, the formula of which simultaneously comprises hydrolyzed coffee yellow sunflower extract, acetyl hexapeptide-8, acetyl octapeptide-3 and dipeptide diaminobutyrylbenzylamide diacetate. The four components can obviously improve the moisture content of the skin cuticle and the fine lines around the eyes under specific mixture ratio, and has the effect of resisting wrinkles.
The small molecular polypeptide has important physiological activity, accurately supplements human nutrition, activates cells, improves the functions and the vitality of the cells, and repairs the cells. Therefore, there is a need for further development of eye essence products containing small molecule polypeptides.
Disclosure of Invention
The invention aims to provide a small-molecule polypeptide eye essence and a preparation method thereof, so as to solve the defects in the background technology.
The invention is realized by the following technical scheme:
a small molecular polypeptide eye essence comprises the following components: oligopeptide mixed solution, micromolecular polypeptide mixed solution, stem cell mixed solution, deep-sea collagen powder and auxiliary agent; the oligopeptide mixed solution consists of oligopeptide-1, oligopeptide-3, oligopeptide-4 and oligopeptide-5; the mixed solution of the small molecular polypeptide consists of tripeptide-1 copper, palmitoyl pentapeptide-4, acetyl tetrapeptide-15, dipeptide-2, acetyl hexapeptide-8, tripeptide-1, nonapeptide-1, palmitoyl tetrapeptide-7 and carnosine.
The auxiliary agent is a common component in an eye essence formula, and comprises but is not limited to a bactericidal preservative, a pH regulator, a gel thickener, a humectant, an anti-allergy agent, a solubilizer and water.
Preferably, the stem cell mixture consists of the following stem cell supernatants: bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, placental mesenchymal stem cells and umbilical cord mesenchymal stem cells; the above-mentioned stem cell supernatants can be mixed according to any proportion, and the preferable weight ratio is as follows: bone marrow mesenchymal stem cells: adipose-derived mesenchymal stem cells: placenta mesenchymal stem cells: umbilical cord mesenchymal stem cells are 1: 2: 2: 1;
the stem cell supernatant is culture solution for stem cell culture, a plurality of growth factors secreted in the stem cell culture process are mainly dissociated in the culture solution, and the growth factors can be obtained by collecting the supernatant. The research shows that the cell factors secreted in the stem cell culture process are easy to be transported and permeated into the dermis layer of the skin by a water channel, and can nourish the epidermis or the dermis stem cells. The stem cell has an autocrine function, can secrete a plurality of active proteins, and the active proteins have a plurality of functions of regulating immunity, regulating cell migration, apoptosis and the like.
The collagen can effectively accelerate the growth of cells in the dermis, activate epidermal cells, maintain the elasticity and firmness of the skin, prevent wrinkles from appearing, and improve or even remove the wrinkles generated by skin aging. However, the collagen extracted from terrestrial animals can activate the activity of the collagen most efficiently at the temperature of more than 35 ℃ to achieve the ideal effect. The human body surface temperature is lower than 35 ℃, and the activity of collagen cannot be well excited. The inventor finds that the activity of the collagen extracted from the deep-sea fish is only activated at the temperature of more than 10 ℃, and the deep-sea collagen powder is added into the eye essence of the invention, so that the activity of the collagen can be fully activated and utilized, and the best effect is achieved.
As a preferred technical scheme, the small-molecule polypeptide eye essence comprises the following components in percentage by weight:
the balance of water, and the sum of the percentage contents of all the components is 100%.
Preferably, the weight ratio of each component in the oligopeptide mixed solution is as follows: oligopeptide-1: oligopeptide-3: oligopeptide-4: oligopeptide-5 is 1: 2: 1: 2.
preferably, the weight percentage of each component in the small molecule polypeptide mixed solution is as follows:
the sum of the percentage contents of all the components is 100 percent.
Among them, tripeptide-1 copper is also known as copper trisupeptide and copper blueness peptide. The copper peptide and the copper compound thereof can be used as an activator and an antioxidant for tissue remodeling, and the copper peptide is also a signal peptide, so that the degradation of a large number of collagen aggregates outside the scar, the synthesis of normal collagen of the skin, the generation of elastin, proteoglycan and glucosaminan, the growth speed and migration of different cell types, inflammation resistance and antioxidant reaction are promoted.
Palmitoyl pentapeptide-4 can penetrate dermis to increase collagen, reverse skin aging process by reconstruction from inside to outside, stimulate proliferation of collagen, elastic fiber and hyaluronic acid, improve skin water content and water locking degree, increase skin thickness, and reduce fine lines.
Acetyl tetrapeptide-15, a polypeptide capable of improving the natural tolerance threshold of skin, can relieve discomfort caused by means of cosmetics and skin quality by improving the tolerance of skin to environmental factors, and achieves the purpose of relieving skin sensitivity.
The dipeptide-2 can improve eye edema and remove dark circles, is an effective angiotensin converting enzyme inhibitor, and can reduce vasoconstriction around eyes and promote blood circulation by inhibiting ACE activity, thereby removing the dark circles.
Acetyl hexapeptide-8, also known as botulinum-like peptide, reduces wrinkles caused by contraction of facial expression muscles and has desirable effects on removing wrinkles around the forehead or eyes. The principle is that nerve transmission muscle contraction information is locally blocked, so that the skin sac nerve conduction is influenced, the facial muscles are relaxed, and the aim of smoothing dynamic lines, static lines and fine lines is achieved; in addition, the activity of elastin can be effectively enhanced, the facial lines can be relaxed, and the skin laxity can be improved.
The first step in melanin formation is the binding of melanocyte stimulating hormone to the MC1 receptor on melanocytes, which then activates tyrosinase to further form melanin. Nonapeptide-1 is a biomimetic peptide, has good matching property with MC1 receptor, and can be used as an antagonist of melanocyte stimulating hormone to prevent tyrosinase from being further activated, thereby reducing and avoiding the formation of melanin.
Carnosine, known by the scientific name β -alanyl-L-histidine, is a dipeptide consisting of two amino acids, alanine β and L-histidine, in crystalline solids, muscle and brain tissues contain very high concentrations of carnosine.
In the above eye essence composition, the pH regulator is preferably, but not limited to, disodium ethylene diamine tetraacetate (EDTA-2Na), the antiseptic preservative is preferably, but not limited to, methyl p-hydroxybenzoate (MP), the gel thickener is preferably, but not limited to, carbomer 940 or 941, the moisturizer comprises hyaluronic acid and small-molecule sodium hyaluronate, the preferable weight ratio of the hyaluronic acid to the small-molecule sodium hyaluronate is 2: 1, the anti-allergic agent is preferably, but not limited to, dipotassium glycyrrhizinate, the solubilizer is preferably, but not limited to, hydrogenated castor oil CO40, and the dextran is preferably, but not limited to, β -dextran, and preferably β -1, 3-dextran.
As a further preferable technical scheme, the small molecule polypeptide eye essence comprises the following components in percentage by weight:
the balance of water, and the sum of the percentage contents of all the components is 100%.
The invention provides a preparation method of the small-molecule polypeptide eye essence, which comprises the following steps:
1. heating the phase A to 75-85 ℃ and completely dissolving;
2. cooling to 45-50 deg.C, adding the material of phase B into phase A, and mixing under vacuum;
3. cooling to 40-45 deg.C, adding phase C, and mixing under vacuum;
4. cooling to 35-38 deg.C, adding pH regulator until pH is 6.0-7.0, and discharging after qualified inspection;
the phase A comprises: water, gel thickeners;
the phase B comprises: glycerin, antiseptic, humectant, antiallergic agent, triethanolamine, solubilizer, dextran, methyl propylene glycol, and isoamyl glycol;
the phase C comprises: oligopeptide mixed liquor, micromolecule polypeptide mixed liquor, stem cell mixed liquor and deep-sea collagen powder.
The eye essence is prepared by carefully compounding a plurality of micromolecular polypeptides and stem cell mixed liquid, has an obvious effect of improving melanin inhibition of eye skin, and has the effects of improving skin elasticity, resisting wrinkles and tightening skin.
Detailed Description
The invention is illustrated below by means of specific examples, without being restricted thereto. All the raw materials are conventional commercial products unless otherwise specified.
Example 1
The small molecular polypeptide eye essence formula comprises the following components:
the preparation method of the micromolecule polypeptide eye essence comprises the following steps:
1. heating the phase A to 80 ℃, and completely dissolving;
2. cooling to 45 ℃, adding the material of the phase B into the phase A, stirring for 40 r/min to achieve uniform mixing, and opening the vacuum to the maximum;
3. cooling to 40 ℃, adding the phase C, and keeping vacuum mixing;
4. cooling to 35-38 deg.C, adding pH regulator until pH is 6.0-7.0, and discharging after qualified inspection;
the phase A comprises: water, gel thickeners;
the phase B comprises: glycerin, antiseptic, humectant, antiallergic agent, triethanolamine, solubilizer, dextran, methyl propylene glycol, and isoamyl glycol;
the phase C comprises: oligopeptide mixed liquor, micromolecule polypeptide mixed liquor, stem cell mixed liquor and deep-sea collagen powder.
Example 2
The small molecular polypeptide eye essence formula comprises the following components:
the preparation method of the micromolecule polypeptide eye essence comprises the following steps:
1. heating the phase A to 85 ℃, and completely dissolving;
2. cooling to 50 ℃, adding the material of the phase B into the phase A, stirring for 40 r/min to achieve uniform mixing, and opening the vacuum to the maximum;
3. cooling to 40 ℃, adding the phase C, and keeping vacuum mixing;
4. cooling to 35-38 deg.C, adding pH regulator until pH is 6.0-7.0, and discharging after qualified inspection;
the phase A comprises: water, gel thickeners;
the phase B comprises: glycerin, antiseptic, humectant, antiallergic agent, triethanolamine, solubilizer, dextran, methyl propylene glycol, and isoamyl glycol;
the phase C comprises: oligopeptide mixed liquor, micromolecule polypeptide mixed liquor, stem cell mixed liquor and deep-sea collagen powder.
Example 3
The small molecular polypeptide eye essence formula comprises the following components:
the preparation method of the micromolecule polypeptide eye essence comprises the following steps:
1. heating the phase A to 80 ℃, and completely dissolving;
2. cooling to 45 ℃, adding the material of the phase B into the phase A, stirring for 40 r/min to achieve uniform mixing, and opening the vacuum to the maximum;
3. cooling to 40 ℃, adding the phase C, and keeping vacuum mixing;
4. cooling to 35-38 deg.C, adding pH regulator until pH is 6.0-7.0, and discharging after qualified inspection;
the phase A comprises: water, gel thickeners;
the phase B comprises: glycerin, antiseptic, humectant, antiallergic agent, triethanolamine, solubilizer, dextran, methyl propylene glycol, and isoamyl glycol;
the phase C comprises: oligopeptide mixed liquor, micromolecule polypeptide mixed liquor, stem cell mixed liquor and deep-sea collagen powder.
Comparative example
The eye essence formulation was the same as example 1 except that the stem cell mixture was not added.
Test example
1. Skin melanin content test:
the skin melanin test probe was used: mexameter MX18, test the level of skin melanin. Based on the principle of spectral absorption (RGB), the amount of melanin in the skin is determined by measuring the amount of reflection of light of a particular wavelength on human skin. The emitter of the instrument probe emits light with three wavelengths to the skin surface, and the receiver detects the light reflected by the skin. Since the amount of emitted light is constant, the amount of light absorbed by the skin and thus the amount of melanin in the skin can be measured.
8 testees with obvious black eye circles are selected. The eyes of the testee can not use any product within 3 days before the test, the pouch (black eye part) is selected as a test area, any 5 points in the area are selected for measurement, and the average value is obtained and recorded. In which the inventive example 1 sample was used for the left eye and the comparative example sample was used for the right eye. The first measurement was made before using the sample and recorded as the initial value. After the test is started, the eye patch is used once in the morning and at night every day, a proper amount of samples are uniformly smeared around eyes to ensure that the eye patch is smeared on a test area and is fully absorbed, and the eye patch is tested once every week after the eye patch is used for four weeks. The test results are shown in table 1:
TABLE 1 difference between melanin content in dark circles and initial value
As can be seen from the above data, the eye essence of example 1 of the present invention is significantly different from the eye essence of the comparative example. Therefore, the eye essence disclosed by the invention has an obvious effect of improving the inhibition of melanin of eye skin.
2. Anti-wrinkle test
The value of the skin elasticity index R7 was measured using a skin elasticity meter Cotomermapa 580 from CK, Germany (constant negative pressure of 450mbar during the test).
30 tested persons with obvious canthus wrinkles are selected and are all women in the age of 35-45 years, and each 10 persons are randomly divided into 1 group and 3 groups. The eyes of the testee can not use any product within 3 days before the test, the canthus skin is selected as a test area, any 5 points in the test area are selected for measurement, and the average value is obtained and recorded. In which the inventive example 1 sample was used for the left eye and the comparative example sample was used for the right eye. The first measurement was made before using the sample and recorded as the initial value. After the test is started, the eye patch is used once in the morning and at night every day, a proper amount of samples are uniformly smeared around eyes to ensure that the eye patch is smeared on a test area and is fully absorbed, and the eye patch is tested once every week after the eye patch is used for four weeks. Specification of indexes: the closer the skin elasticity index R7 is to 1, the better the skin elasticity is. Each set of data from each test was averaged after removing one maximum and one minimum, and the test results are shown in table 2:
TABLE 2 values of the skin elasticity index R7
The test result shows that the skin elasticity is obviously increased after the skin care product is used for two weeks, and the R2 index is close to 1 after the skin care product is used for four weeks, which shows that the skin elasticity of a tested person is greatly improved, and the effect is obviously better than that of a comparative example. The eye essence has the effects of increasing skin elasticity, resisting wrinkles and tightening the skin.
The foregoing shows and describes the general principles, essential features, and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (10)
1. The small-molecule polypeptide eye essence is characterized by comprising the following components: oligopeptide mixed solution, micromolecular polypeptide mixed solution, stem cell mixed solution, deep-sea collagen powder and auxiliary agent; the oligopeptide mixed solution consists of oligopeptide-1, oligopeptide-3, oligopeptide-4 and oligopeptide-5; the mixed solution of the small molecular polypeptide consists of tripeptide-1 copper, palmitoyl pentapeptide-4, acetyl tetrapeptide-15, dipeptide-2, acetyl hexapeptide-8, tripeptide-1, nonapeptide-1, palmitoyl tetrapeptide-7 and carnosine.
2. The small molecule polypeptide eye essence of claim 1, wherein the auxiliary agents comprise antimicrobial preservatives, PH regulators, gel thickeners, humectants, anti-sensitivity agents, solubilizers and water.
3. The small molecule polypeptide eye essence of claim 2, wherein the antimicrobial preservative is methylparaben; the pH regulator is disodium ethylene diamine tetraacetate; the gel thickener is selected from carbomer 940 or 941; the humectant comprises hyaluronic acid and small molecule sodium hyaluronate; the anti-allergy agent is dipotassium glycyrrhizinate; the solubilizer is hydrogenated castor oil CO 40.
4. The small molecule polypeptide eye essence of claim 1, wherein the stem cell mixture consists of the following stem cell supernatants: bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, placental mesenchymal stem cells and umbilical cord mesenchymal stem cells.
5. The small-molecule polypeptide eye essence of claim 3, wherein the stem cell mixture comprises the following components in parts by weight: bone marrow mesenchymal stem cells: adipose-derived mesenchymal stem cells: placenta mesenchymal stem cells: umbilical cord mesenchymal stem cells are 1: 2: 2: 1.
6. the small-molecule polypeptide eye essence of claim 1, wherein the oligopeptide mixed solution comprises the following components in parts by weight: oligopeptide-1: oligopeptide-3: oligopeptide-4: oligopeptide-5 is 1: 2: 1: 2.
7. the small molecule polypeptide eye essence of claim 1, wherein the small molecule polypeptide mixed solution comprises the following components in percentage by weight:
the sum of the percentage contents of all the components is 100 percent.
8. The small-molecule polypeptide eye essence of claim 2, wherein the eye essence comprises the following components in parts by weight:
the balance of water, and the sum of the percentage contents of all the components is 100%.
9. The small molecule polypeptide eye essence of claim 8, comprising the following components in percentage by weight:
the balance of water, and the sum of the percentage contents of all the components is 100%.
10. The method for preparing the small-molecule polypeptide eye essence of any one of claims 1 to 9, which comprises the following steps:
1. heating the phase A to 75-85 ℃ and completely dissolving;
2. cooling to 45-50 deg.C, adding the material of phase B into phase A, and mixing under vacuum;
3. cooling to 40-45 deg.C, adding phase C, and mixing under vacuum;
4. cooling to 35-38 deg.C, adding pH regulator until pH is 6.0-7.0, and discharging after qualified inspection;
the phase A comprises: water, gel thickeners;
the phase B comprises: glycerin, antiseptic, humectant, antiallergic agent, triethanolamine, solubilizer, dextran, methyl propylene glycol, and isoamyl glycol;
the phase C comprises: oligopeptide mixed liquor, micromolecule polypeptide mixed liquor, stem cell mixed liquor and deep-sea collagen powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010027824.3A CN111035609A (en) | 2020-01-10 | 2020-01-10 | Micromolecular polypeptide eye essence and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010027824.3A CN111035609A (en) | 2020-01-10 | 2020-01-10 | Micromolecular polypeptide eye essence and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111035609A true CN111035609A (en) | 2020-04-21 |
Family
ID=70244326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010027824.3A Pending CN111035609A (en) | 2020-01-10 | 2020-01-10 | Micromolecular polypeptide eye essence and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111035609A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714440A (en) * | 2020-06-11 | 2020-09-29 | 上海本正生物工程有限公司 | Essence powder for moistening and tendering skin and preparation method thereof |
| CN112043619A (en) * | 2020-08-20 | 2020-12-08 | 广州优理氏生物科技有限公司 | Peptide composition with repairing effect and preparation method and application thereof |
| CN112190535A (en) * | 2020-10-29 | 2021-01-08 | 溯源生命科技股份有限公司 | Anti-aging repairing microcapsule powder prepared from functional peptide composite hypecoum hainanense stem cells and preparation method thereof |
| CN112618405A (en) * | 2020-12-09 | 2021-04-09 | 珠海为你而美丽化妆品有限公司 | Oligopeptide-containing composition and application thereof in eye mask |
| CN112972284A (en) * | 2021-03-05 | 2021-06-18 | 山东科思达美生物科技有限公司 | Polypeptide composition for eye care and application |
| CN113368004A (en) * | 2021-06-15 | 2021-09-10 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN114569484A (en) * | 2022-03-31 | 2022-06-03 | 成都大华韩艺整形美容医院有限公司 | Injection for improving dark eye circles and fine lines of eyes and preparation method thereof |
| CN114903810A (en) * | 2022-05-31 | 2022-08-16 | 科瑞高(青岛)医药科技有限公司 | Anti-wrinkle composition containing peptide and application thereof |
| CN115400053A (en) * | 2022-08-19 | 2022-11-29 | 广州中草世家化妆品有限公司 | Firming and anti-wrinkle composition and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265120A (en) * | 2016-09-12 | 2017-01-04 | 珠海金肽生物科技有限公司 | Cytokine-like effect of a kind of nine Oligopeptide Compositions and cosmetic applications |
| CN107898657A (en) * | 2017-12-08 | 2018-04-13 | 广州赛莱拉干细胞科技股份有限公司 | Eye mask containing stem cell secretion factors |
| CN107961198A (en) * | 2017-12-08 | 2018-04-27 | 广州赛莱拉干细胞科技股份有限公司 | Eye cream containing stem cell secretory factors |
| CN108721200A (en) * | 2018-06-07 | 2018-11-02 | 武汉赛云博生物科技有限公司 | A kind of preparation method and application of the excretion body cosmetic formulation in human mesenchymal stem cell source |
| CN108852894A (en) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing |
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
-
2020
- 2020-01-10 CN CN202010027824.3A patent/CN111035609A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265120A (en) * | 2016-09-12 | 2017-01-04 | 珠海金肽生物科技有限公司 | Cytokine-like effect of a kind of nine Oligopeptide Compositions and cosmetic applications |
| CN107898657A (en) * | 2017-12-08 | 2018-04-13 | 广州赛莱拉干细胞科技股份有限公司 | Eye mask containing stem cell secretion factors |
| CN107961198A (en) * | 2017-12-08 | 2018-04-27 | 广州赛莱拉干细胞科技股份有限公司 | Eye cream containing stem cell secretory factors |
| CN109984952A (en) * | 2017-12-29 | 2019-07-09 | 广州佳洁化妆品有限公司 | A kind of Essence and preparation method of the compounding removing wrinkle and resisting aging containing a variety of small-molecule peptides |
| CN108721200A (en) * | 2018-06-07 | 2018-11-02 | 武汉赛云博生物科技有限公司 | A kind of preparation method and application of the excretion body cosmetic formulation in human mesenchymal stem cell source |
| CN108852894A (en) * | 2018-06-13 | 2018-11-23 | 浙江湃肽生物有限公司 | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111714440A (en) * | 2020-06-11 | 2020-09-29 | 上海本正生物工程有限公司 | Essence powder for moistening and tendering skin and preparation method thereof |
| CN112043619B (en) * | 2020-08-20 | 2023-01-24 | 广州优理氏生物科技有限公司 | Peptide composition with repairing effect and preparation method and application thereof |
| CN112043619A (en) * | 2020-08-20 | 2020-12-08 | 广州优理氏生物科技有限公司 | Peptide composition with repairing effect and preparation method and application thereof |
| CN112190535A (en) * | 2020-10-29 | 2021-01-08 | 溯源生命科技股份有限公司 | Anti-aging repairing microcapsule powder prepared from functional peptide composite hypecoum hainanense stem cells and preparation method thereof |
| CN112618405A (en) * | 2020-12-09 | 2021-04-09 | 珠海为你而美丽化妆品有限公司 | Oligopeptide-containing composition and application thereof in eye mask |
| CN112972284A (en) * | 2021-03-05 | 2021-06-18 | 山东科思达美生物科技有限公司 | Polypeptide composition for eye care and application |
| CN113368004A (en) * | 2021-06-15 | 2021-09-10 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN113368004B (en) * | 2021-06-15 | 2022-07-29 | 郑州三铠化妆品有限公司 | Polypeptide composition with anti-aging and repairing effects and preparation method and application thereof |
| CN114569484A (en) * | 2022-03-31 | 2022-06-03 | 成都大华韩艺整形美容医院有限公司 | Injection for improving dark eye circles and fine lines of eyes and preparation method thereof |
| CN114903810A (en) * | 2022-05-31 | 2022-08-16 | 科瑞高(青岛)医药科技有限公司 | Anti-wrinkle composition containing peptide and application thereof |
| CN114903810B (en) * | 2022-05-31 | 2024-05-03 | 广州上悦生物科技有限公司 | Peptide-containing anti-wrinkle composition and application thereof |
| CN115400053A (en) * | 2022-08-19 | 2022-11-29 | 广州中草世家化妆品有限公司 | Firming and anti-wrinkle composition and preparation method and application thereof |
| CN115400053B (en) * | 2022-08-19 | 2023-08-22 | 广州中草世家化妆品有限公司 | Compact anti-wrinkle composition, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111035609A (en) | Micromolecular polypeptide eye essence and preparation method thereof | |
| CN111686029A (en) | Anti-aging wrinkle-removing composition | |
| CN111904906B (en) | Composition for repairing skin barrier and improving skin resistance and preparation method thereof | |
| CN112043621B (en) | Preservative-free polypeptide composition with anti-aging effect | |
| CN113616566B (en) | Skin care essence for tightening skin and preparation method thereof | |
| KR101244149B1 (en) | Peptide Composition for hyperpigmented skin | |
| SG190342A1 (en) | Cosmetic composition for whitening and improving the resilience of skin | |
| CN111035590A (en) | Micromolecule polypeptide youth essence and preparation method thereof | |
| CN108379215B (en) | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same | |
| CN111067840A (en) | Polypeptide whitening and repairing wash-free mask | |
| CN112656713A (en) | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof | |
| CN111135117A (en) | Small-molecule skin softening essence and preparation method thereof | |
| CN110538093A (en) | polypeptide repair liquid and preparation method thereof | |
| CN113332227A (en) | Soothing and repairing composition and application thereof in cosmetics | |
| CN110496067A (en) | A kind of anti-wrinkle composition and its preparation method and application | |
| CN113576975A (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
| KR101697152B1 (en) | Manufacturing method of cosmetic material having an anti-aging effect using mucin from eel skin | |
| CN104780905B (en) | Make-up and beauty composition containing sea-plant | |
| CN110585111A (en) | Anti-aging cosmetic additive and preparation method thereof | |
| CN113768853B (en) | Whitening and freckle-removing composition, and preparation method and application thereof | |
| CN114588061A (en) | Anti-aging and wrinkle-removing composition, preparation method thereof and skin care product | |
| CN113648241A (en) | High-moisture-retention emulsion and preparation method thereof | |
| CN111568781A (en) | Skin care gel and preparation method thereof | |
| CN109846798B (en) | Composition for tightening skin and cosmetic containing same | |
| CN111991319A (en) | Repair composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200421 |